Knowles Margaret A
Cancer Research UK Clinical Centre, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Carcinogenesis. 2006 Mar;27(3):361-73. doi: 10.1093/carcin/bgi310. Epub 2005 Dec 13.
Cancer of the bladder shows divergent clinical behaviour following diagnosis and it has been proposed that two major groups of tumours exist that develop via different molecular pathways. Low-grade, non-invasive papillary tumours recur frequently, but patients with these tumours do not often suffer progression of disease to muscle invasion. In contrast, tumours that are invading muscle at diagnosis are aggressive and associated with significant mortality. Molecular studies have identified distinct genetic, epigenetic and expression changes in these groups. However, it is not yet clear whether there is direct progression of low-grade superficial tumours to become invasive (a Jeckell and Hyde scenario) or whether in those patients who apparently progress from one form of the disease to the other, different tumour clones are involved and that the two tumour groups are mutually exclusive ('chalk and cheese'). If the latter is true, then attempts to identify molecular markers to predict progression of low-grade superficial bladder tumours may be fruitless. Similarly, it is not clear whether other subgroups of tumours exist that arise via different molecular pathways. There is now a large amount of molecular information about bladder cancer that facilitates examination of these possibilities. Some recent studies provide evidence for the existence of at least one further group of tumours, high-grade superficial papillary tumours, which may develop via a distinct molecular pathway. Patients with such tumours do show increased risk of disease progression and for these there may exist a real progression continuum from non-invasive to invasive. If this is the case, definition of the molecular signature of this pathway and improved understanding of the biological consequences of the events involved will be pivotal in disease management.
膀胱癌在诊断后表现出不同的临床行为,有人提出存在两组主要的肿瘤,它们通过不同的分子途径发展。低级别、非侵袭性乳头状肿瘤经常复发,但患有这些肿瘤的患者疾病进展为肌肉侵袭的情况并不常见。相比之下,诊断时已侵袭肌肉的肿瘤具有侵袭性,且与显著的死亡率相关。分子研究已经在这些组中确定了不同的基因、表观遗传和表达变化。然而,目前尚不清楚低级别浅表性肿瘤是否会直接进展为侵袭性肿瘤(杰基尔与海德的情况),或者在那些明显从一种疾病形式进展为另一种疾病形式的患者中,是否涉及不同的肿瘤克隆,以及这两组肿瘤是否相互排斥(“截然不同”)。如果后者是真的,那么试图识别预测低级别浅表性膀胱肿瘤进展的分子标志物可能是徒劳的。同样,尚不清楚是否存在通过不同分子途径产生的其他肿瘤亚组。现在有大量关于膀胱癌的分子信息,便于研究这些可能性。一些近期研究为至少另一组肿瘤——高级别浅表性乳头状肿瘤的存在提供了证据,这些肿瘤可能通过独特的分子途径发展。患有此类肿瘤的患者确实显示出疾病进展风险增加,对于这些患者,可能存在从非侵袭性到侵袭性的真正进展连续体。如果是这种情况,定义该途径的分子特征并更好地理解所涉及事件的生物学后果对于疾病管理将至关重要。